Luigi Mangione Enters Guilty Plea on Two Federal Counts in UnitedHealthcare CEO Killing

Luigi Mangione pleaded guilty in a Manhattan federal courtroom on 14 August to two federal charges connected to the December 2024 fatal shooting of UnitedHealthcare CEO Brian Thompson, marking a major development in a case that has drawn national attention for nearly two years. Mangione, 28, admitted guilt to interstate stalking resulting in death and stalking through the use of interstate facilities resulting in death, reversing his previous not-guilty plea. Each federal count carries a potential sentence of life in prison. The plea resolves the remaining federal charges against Mangione but does not automatically end the separate criminal case he faces in New York state court, where a murder trial is currently scheduled to begin in September.

During the hearing, Mangione directly acknowledged shooting Thompson and described the actions he took before traveling to New York. Addressing the court, he stated: «I shot Mr. Thompson in Manhattan. I understood that my actions would place him in fear of death or bodily injury. I knew what I was doing was illegal.» Mangione also described researching UnitedHealthcare's annual investor conference and posing as an investor in communications with company leadership to obtain information about the event. His admission provided an unusually detailed acknowledgment of responsibility after he had previously contested the federal case. The guilty pleas were accepted by U.S. District Judge Margaret Garnett, who determined that Mangione was competent to enter them. His federal sentencing is scheduled for 18 December.

Mangione entered what is known as an open plea, meaning his decision to plead guilty was not accompanied by a negotiated plea agreement guaranteeing a particular punishment from federal prosecutors. The two stalking charges can each result in life imprisonment, leaving the eventual sentence for the judge to determine. The federal case had initially been considerably broader and included charges that could have exposed Mangione to the death penalty. In January, however, Judge Garnett dismissed the federal murder-through-use-of-a-firearm count and a related firearms charge, eliminating the possibility of capital punishment in the federal prosecution. The two stalking counts remained, forming the basis of Mangione's guilty plea on Friday and bringing the federal prosecution closer to its conclusion.

Mangione's federal guilty plea now creates a significant legal issue ahead of his separate New York state murder trial, which is scheduled to begin with jury selection on 8 September. His attorneys have previously argued that allowing both prosecutions to proceed would improperly subject him to prosecution twice over the same underlying conduct, and the federal conviction is expected to strengthen their effort to challenge the state case on double jeopardy grounds. The Manhattan District Attorney's Office has opposed that position, maintaining that the state prosecution addresses offenses distinct from the federal stalking charges. Mangione continues to face second-degree murder and weapons charges in state court, where he has pleaded not guilty. Whether Friday's federal plea will delay or otherwise affect that proceeding will now become a central question before the scheduled trial begins.

The state case centers on the killing of Thompson, 50, who was shot from behind outside a Midtown Manhattan hotel on 4 December 2024 as he headed toward UnitedHealth Group's annual investor conference. Mangione fled New York after the shooting and remained the subject of a nationwide search until authorities arrested him five days later at a McDonald's restaurant in Altoona, Pennsylvania. Prosecutors say investigators recovered a 3D-printed pistol from his backpack along with a handwritten notebook containing entries about targeting a health insurance executive. A New York judge ruled in May that the gun and notebook can be presented as evidence at the state trial, rejecting defense arguments seeking to exclude the items over the circumstances surrounding the search that led to their discovery.

A motive

Mangione also used Friday's federal hearing to describe circumstances that he said preceded his decision to target Thompson, providing his own account of a motive that investigators had previously sought to establish through evidence recovered after his arrest. He told the court that years of severe pain from a back injury and his experiences navigating the health insurance system preceded his research into UnitedHealthcare's investor conference. Mangione said he eventually traveled to New York with the intention of killing Thompson after obtaining information about the event and preparing a 3D-printed firearm fitted with a silencer. His federal admission comes nearly two years after Thompson's killing sparked an intense national debate surrounding anger toward the American health insurance industry, while Mangione now awaits federal sentencing on 18 December and the resolution of his separate state prosecution.

Created by humans, assisted by AI.